Neuroendocrine Tumors Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Somatostatin Analogues,(Octreotide, Lanreotide, Pasireotide), Chemotherapeutics (Fluorouracil (5-FU), Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil), Streptozocin, Temozolomide (Temodar), Capecitabine (Xeloda), Dacarbazine (DTIC), Oxaliplatin (Eloxatin)), Targeted Therapeutics, (Sunitinib, Everolimus,Others)), By Indication (Lung NET, Others NET, Gastrointestinal NET, Pancreatic NET), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Region

Neuroendocrine Tumors Therapeutics Market size was valued at US$ 1.6 billion in 2023 and is poised to grow at a significant CAGR of 8.2% from 2024-2030. Neuroendocrine tumors (NET) are abnormal growths that begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumors are rare and can occur anywhere in the body. Most neuroendocrine tumors occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumors can be noncancerous (benign) or cancerous (malignant). NETs will arise from several neuroendocrine cells whose normal functions are to serve at the neuroendocrine interface.

Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands. The neuroendocrine tumor therapeutics market is expected to grow owing to an increase in initiatives taken by various international organizations like the American Association for Cancer Research and the World Health Organization to treat neuroendocrine tumors are expected to drive the growth of the market. AACR provided a $250,000 fund for the Prevention of neuroendocrine tumors. The rise in health care expenditure and an increase in the prevalence rate of neuroendocrine tumors in developing regions is anticipated to drive the neuroendocrine tumor therapeutics market growth.  Though the market is expected to witness healthy growth, the lack of skilled healthcare professionals and lower adoption of advanced treatment technologies in developing economies are key restraints for the neuroendocrine tumors market.

Key Developments:

• On Sep 2024: Ipsen announced final data from CABINET Phase III trial evaluating Cabometyx® (cabozantinib) vs placebo in patients with advanced pancreatic neuroendocrine tumors (pNETs) or advanced extra-pancreatic neuroendocrine tumors (epNETs), both whose diseases have progressed after previous systemic therapy. These data showed statistically significant and clinically meaningful reductions in risk of disease progression or death for Cabometyx relative to placebo of 77% (hazard ratio (HR) 0.23) and 62% (HR 0.38) for patients living with advanced pNETs and epNETs, respectively.
• On April 2024: Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Lutathera® (lutetium Lu 177 dotatate) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. With this approval, Lutathera becomes the first therapy specially reviewed and approved for use in pediatric patients with GEP-NETs.
• On Sep 2022: Eli Lilly and Company have said that the US Food and Drug Administration has accepted for approval the New Drug Application for Retevmo (selpercatinib, 40 mg & 80 mg capsules), which will be indicated for adult patients with locally advanced or metastatic solid tumors harboring a rearranged during transfection (RET) gene fusion who have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. This indication is approved based on results of ORR and duration of response (DOR). Continued approval for this indication may depend upon verification and description of clinical benefit in the confirmatory trial.